Old Web
English
Sign In
Acemap
>
authorDetail
>
Richard Lee
Richard Lee
Bristol-Myers Squibb
Nivolumab
Renal cell carcinoma
Oncology
Internal medicine
Medicine
3
Papers
28
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.
2019
Journal of Clinical Oncology
Hamid Emamekhoo
Mark R. Olsen
Bradley Curtis Carthon
Alexandra Drakaki
Ivor John Percent
Ana M. Molina
Daniel C. Cho
Johanna C. Bendell
Lucio N. Gordan
Arash Rezazadeh Kalebasty
Daniel J. George
Thomas E. Hutson
Richard Lee
Tina C. Young
Jennifer Johansen
Scott S. Tykodi
Show All
Source
Cite
Save
Citations (21)
Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma
2019
Journal for ImmunoTherapy of Cancer
Rui Wang
Junying Zheng
Xiao Shao
Yuko Ishii
Amit Roy
Akintunde Bello
Richard Lee
Joshua Zhang
Megan Wind-Rotolo
Yan Feng
Show All
Source
Cite
Save
Citations (4)
Development of a baseline prognostic cytokine signature that correlates with nivolumab (NIVO) clearance (CL): Translational pharmacokinetic/pharmacodynamic (PK/PD) analysis in patients with renal cell carcinoma (RCC).
2019
Journal of Clinical Oncology
Rui Wang
Xiao Shao
Junying Zheng
Yuko Ishii
Irene Pak
Amit Roy
Akintunde Bello
Richard Lee
Joshua Zhang
Megan Wind-Rotolo
Yan Feng
Show All
Source
Cite
Save
Citations (3)
1